On August 28, 2009
Generic Threat to Optimer Pharma’s Fidaxomicin Antibiotic
The relative efficacy of Optimer Pharma’s investigational antibiotic, fidaxomicin, compared to standard-of-care vancomycin (marketed as Vancocin by drugmaker ViroPharma), remains unclear. Even if Optimer obtains regulatory approval to market fidaxomicin, its commercial success will be limited by the likely appearance of generic vancomycin.
0 Comments